Business Context and Reporting Period
Company: enGene Holdings Inc. (trading as Engene Therapeutics Inc., ticker: ENGN)
Filing Type: Form 8-K (Current Report)
Report Date: September 11, 2025
Reporting Period: Third financial quarter ended July 31, 2025
The filing serves as a notification of the announcement of financial results for the quarter ended July 31, 2025. The detailed financial data is contained in the press release furnished as Exhibit 99.1, which is not included in the provided text.
Key Financial Metrics
The provided Form 8-K text does not contain specific numerical values for the following metrics. Investors must refer to the attached press release (Exhibit 99.1) for details:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not disclose specific material changes in financial condition or operations compared to the prior period. It only confirms the announcement of the Q3 2025 results.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release containing the results but does not include management commentary, forward-looking guidance, or specific risk factors within the 8-K body text.
Unusual Items: No unusual items are described in the provided text.
Legal Disclaimer: The information in this report is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for the statements contained in the attached press release.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash burn figures in the attached Press Release (Exhibit 99.1).
- Confirm the company's cash runway and liquidity position as of July 31, 2025.
- Review any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Check for any changes in the company's financial guidance or outlook for the full fiscal year 2025.
- Confirm the status of the warrants (ENGNW) and any potential dilution impacts.